MAM
MGX icon

Meeder Asset Management’s Metagenomi Therapeutics MGX Stock Holding History

Meeder Asset Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.37K Hold
5,496
– – ﹤0.01% 762
2025
Q4 		$8.9K Hold
5,496
– – ﹤0.01% 697
2025
Q3 		$13K Hold
5,496
– – ﹤0.01% 507
2025
Q2 		$8.13K Buy
5,496
+372
+7% +$583 ﹤0.01% 653
2025
Q1 		$6.97K Buy
+5,124
New +$12.2K ﹤0.01% 709

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Meeder Asset Management's MGX Position: Q1 2026 in Review

Meeder Asset Management held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 5,496 shares worth $7.37K. The position accounts for ﹤0.01% of the portfolio, ranked #762.

Meeder Asset Management first reported a position in MGX in Q1 2025 and has held it in 5 quarters since. The position peaked at $13K in Q3 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Meeder Asset Management held 5,496 shares of Metagenomi Therapeutics worth $7.37K as of Q1 2026.
  • Meeder Asset Management left its Metagenomi Therapeutics share count unchanged in Q1 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q1 2026, its #762 holding.
  • Meeder Asset Management first reported a position in Metagenomi Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Meeder Asset Management's Metagenomi Therapeutics position peaked at $13K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.